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Abstract
Background: Little research has investigated the use of evidence-based guidelines by eating disorder (ED)
therapists, or prescribing of psychotropic medication. Moreover, people with EDs have rarely been surveyed on
these topics, and their clinical and demographic features have not been presented. This study investigated
perception of psychotherapy, psychotropic medication and the clinical characteristics of a community sample of
people with EDs.
Method: An online survey methodology was used to recruit 253 people with eating disorders in the community.
Where feasible, comparisons were made between four types of eating disorder, anorexia nervosa, bulimia nervosa,
and two types of atypical or ‘sub-threshold’ eating disorder.
Results: Unlike medication, reported psychotherapy showed some congruence with evidence based and other
guidance. Most participants were currently receiving either psychotherapy, medication or both, and most had a
severe and chronic ED.
Conclusions: Findings are considered in light of use of evidence-based treatment for EDs, calls for greater
dissemination of cognitive behaviour therapy (CBT); indications that much may be poor quality; and the importance
of what treatments to offer those who are chronically and severely ill. Development of theory and novel treatments
is considered a priority.
Keywords: Eating disorders, Psychotherapy, Medication
Background
Eating disorders (EDs) are associated with significant
mortality and morbidity [1]. They can be difficult to
treat, and there is room for improvement [2]. Not all
community cases receive treatment [3], and not all re-
ceive “evidence-based” treatment [4]. Practice guidelines
[5–8] identify cognitive behaviour therapy (CBT), and
fluoxetine as the best evidence based treatments for bu-
limia nervosa (BN). CBT is recommended for adult an-
orexia nervosa (AN), “based on strong consensus but
weak evidence”([6], p4). Interpersonal psychotherapy
(IPT), cognitive analytic therapy (CAT) and psycho-
dynamic therapies may be useful for AN but ‘evidence
for each of these is modest’ ([8], p14). Guidelines recom-
mend sub-threshold EDs be treated in line with the
disorder they most resemble [5], although an evidence
base is lacking. No drugs are specifically recommended
for AN. Use of a range of psychotropic medication in is
discussed in AN [5, 6, 8], but guidelines urge extreme
caution, and highlight potentially serious hazards.
Few studies have investigated what treatment people
with EDs in the community receive, and whether or not
it meets practice guidelines. Most survey therapists not
patients. Therapists report high use of psychotherapy,
particularly CBT. One study [9] found 196 (74.5 %) of
ED therapists employed CBT for AN, and 181 (83.8 %)
for BN. However, among community clinicians there
was a wider range of approaches. Few used evidence-
based treatment [10], and less than a quarter, 27
(22.9 %), used CBT. When those with EDs in the
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community replied to a research notice, 220 (62.4 %)
with probable BN reported receiving psychotherapy, al-
though few (N = 23, 6.7 %) had received narrowly de-
fined CBT [11]. Psychotherapy received by those with
AN or sub-threshold EDs has not been studied from the
patient’s perspective. Moreover, it has not always been
clear whether therapy was designed to treat the ED. This
is important as EDs have been associated with high
co-morbidity [3].
In relation to psychotropic medication, chart review
found ED patients had often received antidepressants,
N = 102 (50 %), and anxiolytics, N = 32 (16 %), in the
preceding 12 months, although no details of the
drugs, ED or other diagnosis being treated, was pro-
vided [12]. A study of patients with AN found 278
(53 %) reported current use of psychotropic medica-
tion (N = 254, 48.4 %, antidepressants and N = 68,
13 %, antipsychotics) [13]. Exact figures are not pro-
vided, but a wide range of drugs was being taken. In
the only study to report on medication and psycho-
therapy, 225 (63.7 %) with probable BN had received
pharmacological treatment (vs N = 220, 62.4 %, psy-
chotherapy), and 129 (36.6 %) were judged to have
had an adequate course of fluoxetine [11]. As in
other studies, sub-threshold EDs were not studied, no
detail was provided on the drugs taken and whether
the ED, or a different problem, was the target.
Importantly, no study has reported demographic and
clinical information, including data collected using stan-
dardised self-report measures. This would establish a
baseline against which to compare future studies as well
as aid interpretation of findings. The current study
therefore investigated medication and type of psycho-
therapy perceived to have been received by those with
an ED, including sub-threshold diagnoses. Participants
were questioned about treatment specifically for their
ED. Information on demographic characteristics, includ-
ing height and weight, and psychiatric symptoms, using
standardised measures, was collected.
Methods
Participants
A community sample (aged 18-65) was recruited
through internet advertisements on websites such as
Facebook and Beating Eating Disorders (a UK charity).
The text noted “we are looking for women and men
who are currently suffering from an eating disorder (an-
orexia nervosa, bulimia nervosa and eating disorder not
otherwise specified). To take part you must be 18–65
years of age and speak fluent English”.
Design
The study was an internet-based self-report survey.
Procedure
Approval was obtained from the University ethics
board. Participants were provided with a link to the
online survey. An option of completing paper copies
of the questionnaires was available. All participants
gave informed consent.
Measures
Participants were asked their height and weight to calcu-
late current BMI. They were asked details of age, ethni-
city, and occupation and any psychiatric diagnoses, apart
from an ED. Participants completed the following self-
report questionnaires.
Eating disorder diagnostic scale (EDDS; 14)
This brief scale diagnoses EDs. The items map onto the
Diagnostic and Statistical Manual, fifth edition (DSM-V)
criteria [15] for AN and BN, and permit diagnosis of sub-
threshold AN and BN (i.e. where full criteria are not met).
The EDDS possesses good test-retest reliability (r = .87)
and internal consistency (alpha = .89) [14].
Hospital anxiety and depression scale (HADS;16)
This questionnaire contains seven statements related to
anxiety and seven related to depression. A score of 11 or
more indicates probable mood disorder. The sub-scales
are independent, and have good homogeneity and
reliability [17].
Eating attitudes test (EAT; 18)
This measure of eating disturbance is an abbreviated
(26-item) version of the 40-item EAT [19], and the two
are highly correlated (r = .98; 18). Scores above 20 indi-
cate potential eating disturbance. It has good reliability
and validity [18].
Eating disorder examination questionnaire (EDE-Q; 20)
This is a self-report version of the Eating Disorder
Examination [21]. It has 4 subscales, and concerns be-
haviour over the past 28 days. A global score can be
computed. A review indicates good reliability, and
supports its use in identifying cases [22].
Medication and psychotherapy use
Medication use
Participants were asked whether or not they were cur-
rently taking medication in relation to their ED. They
were asked to list all these.
Psychotherapy use
Participants were asked whether or not they had re-
ceived or were currently receiving psychotherapy for
their ED. They were asked to list the type of therapy/
therapies.
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Results
Data analysis
Demographic data were analysed by diagnostic group
using one way analysis of variance for continuous vari-
ables and chi square for categorical data. Chi square was
used to examine group differences in total number re-
ceiving psychotropic medication and current and past
psychotherapy. Further statistical testing was not under-
taken due to small numbers in most categories.
Response
Four hundred and fifty four people started, and 260
(57 %) completed, the survey. Two hundred and fifty
three (97.3 %) were diagnosed with AN, BN, or sub-
threshold ED using the EDDS.
Diagnosis
Extracting data from the EDDS, and using the algorithm
[13], forty-four participants had a DSM-V [15] diagnosis
of AN; 30 a diagnosis of atypical (sub-threshold) AN,
126 a diagnosis of BN, and 53 a diagnosis of BN of low
frequency and/or duration (sub-threshold BN).
Demographic results
Two hundred and forty six participants were female and
seven were male (one AN, three BN and three sub-
threshold BN). Demographic details (continuous vari-
ables) for each diagnostic group are in Table 1 and (cat-
egorical variables) in Table 2. There was no significant
difference between the four groups in age (F = 1.53, df = 3,
248, p = .21). Most participants were in their late 20s.
There was a significant difference between groups in BMI
(F = 13.3, df = 3, 250, p < .001). Post hoc Tukey tests indi-
cated those with AN had a lower mean BMI than all other
groups (all p values < .03). The distribution of Caucasian/
non Caucasian participants did not differ (chi2 = 1.62 df =
3, p = .65), and most were Caucasian. The majority lived
in the United Kingdom or USA. Socioeconomic Status
(SES) was classified using the Office of National Statistics
Standard Occupational Classification [23]. Extra categories
were added for students, the unemployed and retired. The
majority were students although a significant number
were managers/professionals or unemployed. There were
no significant differences in occupation in the four groups
(chi2 = 6.62, df = 9, p = .67). Over a third had been a psy-
chiatric inpatient, particularly those with AN and sub-
threshold AN (chi2 = 13.9, df = 3, p = .003). Mean duration
of ED was similar across the sample (11.3 years, SD =
9.37), (F = 1.64, df = 3, 249, p = .18). Twenty four (11.3 %)
reported a current psychiatric diagnosis other than an ED,
with no differences between the groups (chi2 = 3.96, df = 3,
p = .27).
Self-report questionnaires
Scores for the diagnostic groups on the questionnaires
are in Table 1. There was a significant difference be-
tween the groups in EAT scores (F = 10.29, df = 3252,
p = <.001). Post hoc Tukey tests found the sub-
threshold BN group had a significantly lower score
than the other groups (all p values < .002). There was
a significant difference between groups in EDE-Q
total score (F = 13.76, df = 3, 252, p < .001). Post hoc
Tukey tests indicated a lower score in the sub-
threshold BN group compared to all other groups (all
p values < =.001). There was no significant difference be-
tween the four groups in HADS depression (F = 1.8, df =
3252, p = .15) or anxiety (F = 1.59, df = 3, 252, p = .19).
Medication use
Table 3 displays psychotropic medication use for the
four diagnostic groups and whole sample. There was
a significant difference between the groups (chi2 =
9.62, df = 3, p = .02) in whether or not any psycho-
tropic medication was being taken. It was most
Table 1 Demographic and clinical characteristics of the sample – continuous variables
AN AN-sub-threshold BN BN-sub-threshold Total
(N = 44) (N = 30) (N = 126) (N = 53) (N = 253)
Mean SD Mean SD Mean SD Mean SD Mean SD
Age 28.0 10.3 26.3 9.4 26.1 8.5 29.4 12.3 27.1 9.8
Body Mass Index 15.8 1.2 20.2 6.1 23.1 8.1 22.8 6.8 21.4 7.3
EAT 49.4 13.3 46.8 14.7 42.6 14.0 33.5 18.4 42.4 15.8
EDE-Q 4.6 1.1 4.8 0.9 4.8 0.9 3.7 1.6 4.6 1.2
HADS-depression 11.0 4.5 10.6 4.3 10.0 4.6 8.9 4.9 10.0 4.6
HADS-anxiety 15.1 4.4 14.6 3.6 14.0 3.9 13.3 4.8 14.1 4.2
Duration of ED (years) 13.3 9.4 9.3 7.5 10.6 9.0 12.5 9.4 11.3 9.4
Key: AN Anorexia Nervosa, AN-sub-threshold, BN Bulimia Nervosa, BN-sub-threshold, EAT Eating Attitudes Test, EDE-Q Eating Disorder Examination – Questionnaire,
HADS Hospital Anxiety and Depression Scale
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common in AN (N = 26, 59 %), and least common in
BN (N = 41, 32.5 %). Overall, a substantial minority
(N = 54, 10.2 %) were taking two or more psycho-
tropic drugs. Antidepressants were the most common
(taken by N = 107, 42.3 %), with N = 50, 19.8 % on
Selective Serotonin Reuptake Inhibitors and N = 21,
8.3 %, on Selective Norepinephrine Reuptake Inhibi-
tors. A minority were taking fluoxetine (N = 15,
5.9 %); four (3.2 %) had BN and two (3.8 %) had sub-
threshold BN. A significant minority were taking anti-
anxiety drugs (N = 36, 14.2 %), mood stabilisers (N =
26, 10.3 %) and antipsychotics (N = 21, 8.3 %).
Psychotherapy use
Table 4 displays current and past psychotherapy use for
the whole sample and each ED diagnosis. Just under half
were receiving current psychotherapy (N = 123, 48.6 %),
with no group differences (chi2 = 4.97, df = 3, p = .17).
CBT was being received by N = 110, 23.3 % of the total
sample, and family therapy by a small number of those
with AN (N = 6, 13.6 %) and sub-threshold AN (N= 3,
10 %). Overall, few were receiving Cognitive Analytic
Therapy (CAT) (N = 2, 0.8 %), Dialectical Behaviour
Therapy (DBT) (N = 9, 3.6 %), Interpersonal Psychother-
apy (IPT) or Counselling (N = 8, 3.2 %). A number did
not know what type of psychotherapy they were
receiving (N = 44, 17.4 %). Some were receiving a
range of “other” forms of therapy (N = 25, 9.9 %).
81.8 % (N = 207) had received past psychotherapy, with
no group differences (chi2 = 4.0, p = .26). Just under half
had received CBT (N = 110, 47 %). A number with AN
(N = 14, 31.8 %), or sub-threshold AN (N = 12, 40 %)
had received family therapy. A significant minority
had received psychodynamic therapy (N = 43, 17 %),
some had received CAT (N = 13, 5.1 %), DBT (N = 3,
1.2 %), IPT or Counselling (N = 7, 2.8 %). A number
did not know what type of therapy they had received
(N = 61, 24.1 %).
Combination therapies
Just under half who had received past psychological ther-
apy were currently receiving it. Nearly one third (N = 75,
Table 2 Demographic and clinical characteristic of the sample – categorical variables
AN AN-sub-threshold BN BN-sub-threshold Total
(N = 44) (N = 30) (N = 126) (N = 53) (N = 253)
N % N % N % N % N %
Ethnicity
Caucasian 41 93.2 29 96.7 114 90.5 46 86.8 230 90.9
Non Caucasian 3 6.8 1 2.3 12 9.5 3 5.7 19 7.5
Country
United Kingdom 21 47.8 11 36.7 47 37.5 27 50.9 91 36.0
USA 12 27.3 15 50.0 44 35.0 16 30.2 78 30.8
Canada, Australia, New Zealand 8 18.2 4 13.3 18 14.3 3 5.7 31 12.3
SES
Managers/professionals 8 18.2 4 13.3 20 15.9 6 11.3 38 15.0
Associate professionals 3 6.8 2 6.7 5 4.0 6 11.3 16 6.3
Students 14 31.8 15 50.0 44 35.0 22 41.5 95 37.5
Unemployed 6 13.6 6 20.0 23 18.3 6 11.3 41 16.2
ED/psychiatric variables
Been a psychiatric inpatient 26 59.0 14 46.7 37 29.4 16 30.2 93 36.8
Other psychiatric diagnosis
Depression 3 6.8 1 2.3 7 5.6 2 3.8 13 5.1
Anxiety 3 6.8 0 0 2 1.6 0 0 5 2.0
Borderline personality disorder 2 4.5 0 0 4 3.2 0 0 6 2.4
Bipolar disorder 1 2.3 1 2.3 4 3.2 0 0 6 2.4
PTSD 3 6.8 0 0 3 2.4 1 1.9 7 2.8
OCD 0 0 0 0 3 2.4 0 0 3 1.2
Self-harm 0 0 0 0 1 0.8 0 0 1 0.4
ADHD 0 0 0 0 0 0 0 0 1 0.4
Key: AN Anorexia Nervosa, AN-sub-threshold, BN Bulimia Nervosa, BN-sub-threshold SSRIs Selective
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29.6 %) was currently receiving both psychological therapy
and psychotropic medication (highest in AN, N = 19,
43.2 %). Thirty people (11.9 %) were currently taking
medication only (highest in sub-threshold BN, N = 9,
17 %). Thirty-nine people (18.3 %) were receiving psy-
chotherapy only (highest in AN, N = 27, 61.4 %).
Overall, just over one quarter were not receiving current
treatment (N = 72, 28.5 %), highest in BN (N = 47, 37.3 %)
and sub-threshold AN (N= 10, 33.3 %), and lowest in AN
(N = 8, 18.2 %), and sub-threshold BN (N= 7, 13.2 %).
Discussion
A community sample was asked about treatment for their
ED. Just under half were taking psychotropic medicine,
with few taking fluoxetine. Nearly half were receiving psy-
chotherapy, often CBT. A wide range of psychotropic and
psychological therapies was being received. Most had pre-
viously received psychotherapy. Just under a third was re-
ceiving both medication and psychotherapy.
The sample was demographically similar to clinical
samples (including AN, BN and sub-threshold diagnoses
in the community, 24), but with more severe psycho-
pathology and longer illness duration. Indeed, our sam-
ple had severe and chronic EDs, and the findings should
be interpreted in this light. Interestingly, those with sub-
threshold diagnoses had symptom scores similar to those
with AN or BN, and illness of similar duration, suggest-
ing sub-threshold disorders can also be severe and
chronic. To date, treatment received has usually been
studied only in AN or BN, has not investigated medica-
tion and psychotherapy, nor reported ED symptom se-
verity, thus enabling therapy data to be contextualised.
Unlike most studies we asked patients (not clinicians)
what treatment was received, gaining a view of what pa-
tients perceived (particularly important for type of psycho-
therapy). Most had previously received psychotherapy for
their ED, including those with sub-threshold diagnoses.
This is consistent with the finding that many who present
to services have such diagnoses, and that these are rela-
tively common ED diagnoses [25]. Nearly half were cur-
rently taking psychotropic medication, and just over half
were receiving psychotherapy. Some (32.9 %) were
Table 3 Summary of medication taken by sample
AN AN-sub-threshold BN BN-sub-threshold Total
(N = 44) (N = 30) (N = 126) (N = 53) (N = 253)
N % N % N % N % N %
No medication 17 38.6 14 46.7 77 69.1 31 58.5 139 54.9
One psychiatric drug 14 31.8 9 30 22 17.5 8 15.1 53 20.9
Two psychiatric drugs 5 11.4 3 10.0 13 10.3 5 9.4 26 10.3
Three psychiatric drugs 3 6.8 4 13.3 7 5.6 3 5.7 17 6.7
Four psychiatric drugs 4 9.1 0 0 2 1.6 2 3.8 8 3.2
Five psychiatric drugs 0 0 0 0 3 2.4 0 0 3 1.2
Total on any psychiatric medication 26 59.0 16 53.3 41 32.5 25 47.2 108 42.7
Anti-anxiety 7 15.9 5 16.7 12 9.5 6 11.3 36 14.2
Hypnotics 0 0 0 0 4 3.2 2 3.8 6 2.4
Psycho-stimulants 2 4.5 0 0 3 2.4 2 3.8 7 2.8
Tricyclic antidepressants 1 2.3 0 0 1 0.8 1 1.9 3 1.2
SSRIs 20 45.5 11 36.7 8 14.3 11 20.8 50 19.8
Fluoxetine 4 9.1 5 16.7 4 3.2 2 3.8 15 5.9
SARIs 2 4.5 0 0 3 2.4 0 0 5 2.0
SNRIs 1 2.3 2 6.7 15 11.9 3 3.8 21 8.3
NaSSRAs 1 2.3 1 3.3 4 3.2 1 1.9 7 2.8
NDRIs 1 2.3 0 0 5 4.0 0 0 6 2.4
Melatonergic agonists 0 0 0 0 1 0.8 0 0 1 0.4
Antidepressant (unspecified) 1 2.3 0 0 0 0 1 1.9 2 0.8
Total on anti-depressants 27 61.4 14 46.7 41 32.5 25 47.2 107 42.3
Mood stabilisers 3 6.8 4 13.3 16 12.7 3 3.8 26 10.3
Antipsychotics 7 15.9 2 6.7 8 6.3 4 7.5 21 8.3
Key: AN Anorexia Nervosa, AN-sub-threshold, BN Bulimia Nervosa, BN-sub-threshold, SSRIs Selective Serotonin Reuptake Inhibitors,
SARIs Serotonin Antagonist and Reuptake Inhibitor, SNRIs Serotonin Norepinephrine Reuptake Inhibitor, NaSSAs Noradrenergic and Specific Serotinergic
Antidepressant, NDRIs Norepinephrine Dopamine Reuptake Inhibitor
Cooper and Kelland Journal of Eating Disorders  (2015) 3:45 Page 5 of 8
receiving both. Receipt of psychotropic medication is simi-
lar to previous studies [12, 13]. However, the percent (7 %)
receiving fluoxetine was markedly lower [11]. Indeed, it is
surprisingly low, given fluoxetine is recommended by
NICE for BN and sub-threshold BN. However, some
guidelines are less enthusiastic about prescribing fluoxet-
ine, highlighting lack of follow-up, and high attrition [8].
Overall, however, nearly half was taking an antidepressant,
often an SSRI, but like previous studies, a wide range of
other antidepressants [13]. A significant minority were
taking anti-anxiety drugs, mood stabilisers, and antipsy-
chotics. This is consistent with in-patients with AN [13]
and extends these findings to other diagnoses and the
community. However, it is important to note that none of
these medications has an evidence base in EDs, and some
may be contraindicated because of safety, particularly in
AN [6–8, 13]. Just over half our sample was receiving
CBT, and some with AN or sub-threshold AN, family
therapy. This is consistent with the evidence base in BN,
and recommendations for AN. However, several other
psychological therapies were being received, most with
minimal evidence base in EDs. Worryingly, many did not
know what type of psychological therapy they were, or
had been, receiving. Over half receiving psychotherapy
had previously received psychotherapy, suggesting it had
not resolved the ED, they had experienced a recurrence of
symptoms or perhaps had not completed or engaged with
treatment, all of which are known problems in EDs. These
possibilities seem particularly likely given the chronicity
and severity of the sample. For example, use of non-
evidence based therapy currently may be due to previous
failure of evidence-based treatment. One particular limita-
tion here is that while we asked about previous psycho-
therapy we did not ask about previous medication; thus
Table 4 Summary of psychotherapy received by sample
AN AN-sub-threshold BN BN-sub-threshold Total
(N = 44) (N = 30) (N = 126) (N = 53) (N = 253)
N % N % N % N % N %
Current therapy 27 61.4 16 53.3 61 48.4 19 35.8 123 48.6
CBT 14 31.8 10 33.3 25 19.8 10 18.9 110 23.3
Schema focussed therapy 1 2.3 0 0 0 0 0 1 0.4
Family therapy 6 13.6 3 10.0 5 4.0 2 3.8 16 6.3
Psychodynamic therapy 2 4.5 2 6.7 7 5.6 2 3.8 13 5.1
CAT 1 2.3 0 0 1 0.8 0 0 2 0.8
DBT 1 2.3 2 6.7 6 4.8 0 0 9 3.6
Counselling 1 4.5 2 6.7 3 2.4 2 3.8 8 3.2
Other 7 15.9 5 16.7 10 7.9 3 5.7 25 9.9
Don’t know type of therapy 5 11.4 6 20.0 21 16.7 12 22.4 44 17.4
Past therapy 41 93 25 83.3 102 81 39 73.6 207 81.8
CBT 23 52.3 19 63.3 52 41.3 25 47.2 119 47.0
Schema focussed therapy 1 2.3 2 6.7 4 3.2 1 1.9 8 3.2
Family therapy 14 31.8 12 40.0 22 17.5 12 22.4 60 23.7
Psychodynamic therapy 11 25.0 4 13.3 18 14.3 10 18.9 43 17.0
CAT 3 6.8 1 3.3 4 3.2 5 9.4 13 5.1
DBT 2 4.5 0 0 2 1.6 1 1.9 3 1.2
Counselling 2 4.5 2 6.7 2 1.6 1 1.9 7 2.8
Other 3 6.8 1 3.3 9 7.1 4 7.5 17 6.7
Don’t know type of therapy 8 18.2 5 16.7 38 30.2 10 18.9 61 24.1
Current and past psychological therapy 27 61.4 13 43.3 53 42.1 17 32.1 110 43.5
Combination therapy 19 43.2 11 36.7 36 28.6 9 17.0 75 29.6
Psychotherapy only 27 61.4 5 16.7 23 18.2 10 18.9 56 39.5
Medication only 7 15.9 5 16.7 13 10.3 9 17.0 30 11.9
No therapy 8 18.2 10 33.3 47 37.4 7 13.2 72 28.5
Key: AN Anorexia Nervosa, AN-sub-threshold, BN Bulimia Nervosa, BN-sub-threshold, CBT Cognitive Behaviour Therapy, CAT Cognitive Analytic Therapy, DBT Dialectical
Behaviour Therapy
Cooper and Kelland Journal of Eating Disorders  (2015) 3:45 Page 6 of 8
previous use of evidence-based medication could not be
evaluated, and it may be that fluoxetine (for example) had
not proved helpful for our patients in the past and thus
more diverse drugs had been prescribed. Self-reported
comorbidity was low, and the reason for this is unclear.
One possibility is that it is less likely to be identified and
labelled outside highly structured research, another that it
is often considered a secondary problem.
Despite encouraging trends for CBT and family ther-
apy, the fit between our data and ED (evidence-based)
practice guidelines is not close. A plethora of different
treatments (some evidence based, but many not) had
been, and were being, received. Explanations for treat-
ment failure in EDs vary from lack of dissemination of
CBT to poor patient motivation/engagement [26]. While
these may play a role, what is striking about the current
sample is that all had a severe and chronic ED. An alter-
native to these different explanations for treatment fail-
ure may be that, in fact, we currently lack effective,
powerful treatments for EDs. The question is not, why
don’t more people receive CBT or fluoxetine? It may not
be why is better quality treatment not available? The
question may be why is there not more emphasis on the
development of theory to inform novel treatment ap-
proaches? For some with a chronic and severe ED the
range of treatments tried (understandably given failure
to recover) is truly staggering.
The study has limitations. The majority of participants
had received treatment; the sample is unlikely therefore
to represent all those with EDs in the community (27).
Diagnosis was completed using self-report questionnaire,
likely less valid than clinician obtained diagnosis. The
sample was relatively ill with severe symptoms and a
chronic course, thus not representative of those with less
severe symptoms and recent onset. Indeed, there may
have been a selection bias in that the survey appealed to
those with chronic and severe EDs. Self-report of medi-
cation and psychotherapy may be less reliable and valid
than chart review. Data on quality, frequency, duration
or dosage of the interventions, or individual adherence,
was not obtained. Finally, given clinician self-report of
evidence based treatment may lack validity [4], this may
also be problematic for patient self-report of these.
Conclusions
It is easy to criticise non-evidence based psychotherapy,
and the apparently widespread use of psychotropic
medication that lacks an evidence base for EDs. As their
scores and history indicate, this sample is seriously and
chronically ill. It is not easy for therapists and services
to do nothing. If CBT has failed (however well deliv-
ered), it is hard to justify providing it again, and perhaps
understandably, patients and therapists may seek alter-
native psychotherapies. It is not clear why fluoxetine is
given or taken so rarely (some suggestions are given
above). However, it is clear that cautious and carefully
monitored use of a number of non-evidenced based psy-
chotropic medications can, as suggested by the APA
Practice Guidelines for the Treatment of Patients with
EDs [6], provide some relief from troubling symptoms,
even if not directly treating the ED. In the absence of
any real ED specific medication this is likely to be a use-
ful option for some, and one that it would not be appro-
priate to withhold from patients. The same may also be
true of some non-evidence based psychotherapy. Finally,
it may be mistaken to conclude that individuals in our
sample have not benefitted from at least some of the in-
terventions received. While efficacy studies focus on
modifying diagnostic features, clinicians treating those
who are very ill, are likely to be rather more concerned
with quality of life. A wide range of therapies may be
needed to achieve this, including those not specifically
focussed on the ED.
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